TABLE OF CONTENTS
1 INTRODUCTION 11
1.1 OBJECTIVES OF THE STUDY 11
1.2 MARKET DEFINITION 11
1.3 OVERVIEW OF ARGENTINA GASTRIC CANCER TREATMENT MARKET 11
1.4 CURRENCY AND PRICING 13
1.5 LIMITATIONS 13
1.6 MARKETS COVERED 14
2 MARKET SEGMENTATION 16
2.1 MARKETS COVERED 16
2.2 GEOGRAPHICAL SCOPE\ 17
2.3 YEARS CONSIDERED FOR THE STUDY 17
2.4 DBMR TRIPOD DATA VALIDATION MODEL 18
2.5 MULTIVARIATE MODELLING 22
2.6 MARKET LIFELINE CURVE 22
2.7 DBMR MARKET POSITION GRID 23
2.8 VENDOR SHARE ANALYSIS 24
2.9 MARKET END USER COVERAGE GRID 25
2.10 SECONDARY SOURCES 26
2.11 ASSUMPTIONS 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 30
4.1 PESTEL ANALYSIS 31
4.2 PORTERS FIVE FORCES 32
5 EPIDEMIOLOGY 33
6 REGULATIONS OF ARGENTINA GASTRIC CANCER TREATMENT MARKET 34
7 PIPELINE ANALYSIS FOR ARGENTINA GASTRIC CANCER TREATMENT 36
8 MARKET OVERVIEW 37
8.1 DRIVERS 39
8.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA 39
8.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING 39
8.1.3 HIGH INCIDENCE OF OBESITY 40
8.1.4 RECENT ADVANCEMENT IN GASTRIC CANCER TREATMENT 40

8.2 RESTRAINTS 41
8.2.1 HIGH COST OF TESTING AND MEDICATIONS 41
8.2.2 ADVERSE SIDE-EFFECTS OF GASTRIC CANCER TREATMENT 42
8.3 OPPORTUNITIES 43
8.3.1 INCREASING DRUG APPROVALS 43
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS 43
8.4 CHALLENGES 44
8.4.1 OLD AGE CHALLENGES 44
8.4.2 ALTERNATIVE GASTRIC CANCER THERAPIES 44
9 IMPACT OF COVID-19 PANDEMIC ON THE ARGENTINA GASTRIC CANCER TREATMENT MARKET 45
9.1 PRICE IMPACT 45
9.2 IMPACT ON DEMAND 45
9.3 IMPACT ON SUPPLY CHAIN 45
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS 46
9.5 CONCLUSION 46
10 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY TYPE 47
10.1 OVERVIEW 48
10.2 ADENOCARCINOMA 51
10.3 GASTROINTESTINAL STROMAL TUMOR 51
10.4 CARCINOID TUMOR 51
10.5 LYMPHOMA 51
10.6 OTHERS 52
11 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY STAGES 53
11.1 OVERVIEW 54
11.2 STAGE III 57
11.3 STAGE II 57
11.4 STAGE IV 57
11.5 STAGE I 57
11.6 OTHERS 57

12 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY TREATMENT 58
12.1 OVERVIEW 59
12.2 CHEMOTHERAPY 62
12.2.1 OXALIPLATIN 62
12.2.2 CISPLATIN 62
12.2.3 FLUOROURACIL 62
12.2.4 DOCETAXEL 62
12.2.5 CAPECITABINE 62
12.2.6 CARBOPLATIN 63
12.2.7 EPIRUBICIN 63
12.2.8 PACLITAXEL 63
12.2.9 IRINOTECAN 63
12.2.10 OTHERS 63
12.3 TARGETED THERAPY 63
12.3.1 MONOCLONAL ANTIBODY THERAPY 64
12.3.1.1 TRASTUZUMAB (HERCEPTIN) 64
12.3.1.2 RAMUCIRUMAB 64
12.3.2 MULTIKINASE INHIBITORS 64
12.3.2.1 SUNITINIB 64
12.3.2.2 REGORAFENIB 64
12.4 IMMUNE CHECKPOINT INHIBITORS 65
12.5 OTHERS 65
13 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 66
13.1 OVERVIEW 67
13.2 PARENTERAL 70
13.2.1 INTRAVENOUS 70
13.2.2 SUBCUTANEOUS 70
13.2.3 OTHERS 70
13.3 ORAL 70
13.3.1 TABLET 71
13.3.2 CAPSULE 71
13.3.3 OTHERS 71
13.4 OTHERS 71

14 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY END USER 72
14.1 OVERVIEW 73
14.2 HOSPITALS 76
14.3 SPECIALITY CLINICS 76
14.4 RESEARCH & ACADEMIC INSTITUTES 76
14.5 OTHERS 76
15 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 77
15.1 OVERVIEW 78
15.2 HOSPITAL PHARMACY 81
15.3 RETAIL PHARMACY 81
15.4 OTHERS 81
16 ARGENTINA GASTRIC CANCER TREATMENT MARKET: COMPANY LANDSCAPE 82
16.1 COMPANY SHARE ANALYSIS: ARGENTINA 82
17 SWOT ANALYSIS 83
18 COMPANY PROFILE 84
18.1 MERCK & CO., INC. 84
18.1.1 COMPANY SNAPSHOT 84
18.1.2 REVENUE ANALYSIS 84
18.1.3 PRODUCT PORTFOLIO 85
18.1.4 RECENT DEVELOPMENTS 85
18.2 ASTRAZENECA 86
18.2.1 COMPANY SNAPSHOT 86
18.2.2 REVENUE ANALYSIS 86
18.2.3 PRODUCT PORTFOLIO 87
18.2.4 RECENT DEVELOPMENTS 87
18.3 PFIZER INC. 89
18.3.1 COMPANY SNAPSHOT 89
18.3.2 REVENUE ANALYSIS 89
18.3.3 PRODUCT PORTFOLIO 90
18.3.4 RECENT DEVELOPMENT 90
18.4 ELI LILLY AND COMPANY 91
18.4.1 COMPANY SNAPSHOT 91
18.4.2 REVENUE ANALYSIS 91
18.4.3 PRODUCT PORTFOLIO 92
18.4.4 RECENT DEVELOPMENT 92

18.5 NOVARTIS AG 93
18.5.1 COMPANY SNAPSHOT 93
18.5.2 REVENUE ANALYSIS 94
18.5.3 PRODUCT PORTFOLIO 94
18.5.4 RECENT DEVELOPMENT 94
18.6 TEVA PHARMACEUTICAL INDUSTRIES LTD 95
18.6.1 COMPANY SNAPSHOT 95
18.6.2 REVENUE ANALYSIS 95
18.6.3 PRODUCT PORTFOLIO 96
18.6.4 RECENT DEVELOPMENT 96
18.6.4.1 EXPANSION: 96
18.7 GENENTECH, INC. (A SUBSIDIARY OF A SUBSIDIARY OF F. HOFFMANN-LA ROCHE) 97
18.7.1 COMPANY SNAPSHOT 97
18.7.2 REVENUE ANALYSIS 97
18.7.3 PRODUCT PORTFOLIO 98
18.7.4 RECENT DEVELOPMENT 98
18.8 LABORATORIO VARIFARMA SA 99
18.8.1 COMPANY SNAPSHOT 99
18.8.2 PRODUCT PORTFOLIO 99
18.8.3 RECENT DEVELOPMENT 99
18.8.3.1 EXPANSION: 99
18.9 TUTEUR 100
18.9.1 COMPANY SNAPSHOT 100
18.9.2 PRODUCT PORTFOLIO 100
18.9.3 RECENT DEVELOPMENT 100
18.10 CELNOVA PHARMA 101
18.10.1 COMPANY SNAPSHOT 101
18.10.2 PRODUCT PORTFOLIO 101
18.10.3 RECENT DEVELOPMENT 101
18.10.3.1 PARTNERSHIP: 101
18.11 ERIOCHEM SA 103
18.11.1 COMPANY SNAPSHOT 103
18.11.2 PRODUCT PORTFOLIO 103
18.11.3 RECENT DEVELOPMENT 103
18.12 GRUPO BIOTOSCANA 104
18.12.1 COMPANY SNAPSHOT 104
18.12.2 REVENUE ANALYSIS 104
18.12.3 PRODUCT PORTFOLIO 105
18.12.4 RECENT DEVELOPMENT 105

18.13 LABORATORIOS IMA 107
18.13.1 COMPANY SNAPSHOT 107
18.13.2 PRODUCT PORTFOLIO 107
18.13.3 RECENT DEVELOPMENTS 107
18.14 BRISTOL-MYERS SQUIBB COMPANY 108
18.14.1 COMPANY SNAPSHOT 108
18.14.2 REVENUE ANALYSIS 108
18.14.3 PRODUCT PORTFOLIO 109
18.14.4 RECENT DEVELOPMENTS 109
18.15 SANOFI 110
18.15.1 COMPANY SNAPSHOT 110
18.15.2 REVENUE ANALYSIS 110
18.15.3 PRODUCT PORTFOLIO 110
18.15.4 RECENT DEVELOPMENTS 111
19 QUESTIONNAIRE 112
20 RELATED REPORTS 115

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.